Evidence Hub

Formulating And Optimizing Gastroretentive Floating Dexlansoprazole for Enhanced Bioavailability In Vitro And In Vivo

Adimulka Sandhya, P. Rao, M. P. Kusuma

African Journal of Biomedical Research, 2024

Abstract

Background: Gastroesophageal reflux disease (GERD) is commonly treated with the proton pump inhibitor dexlansoprazole (DLS). Its limited absorption window in the upper gastrointestinal (GI) tract, pH-dependent solubility, and brief plasma half-life, however, restrict its bioavailability and therapeutic effectiveness. Gastroretentive floating drug delivery systems (GRDDS) present a viable approach to overcoming these constraints by improving systemic absorption and extending the stomach residence duration.

objective : The objective of this study was to improve the bioavailability and therapeutic profile of Dexlansoprazole by developing, optimizing, and evaluating different GRDDS formulations using a factorial approach, with an emphasis on in-vitro and in-vivo parameters.

Methods: Gas-generating agents, swelling polymers, and mucoadhesive components were used to create three different GRDDS formulations: floating microspheres, bilayer tablets, and matrix tablets. Formulation variables were optimized using response surface approach and factororial design. Under simulated stomach circumstances (pH 1.2), physical-chemical characteristics, buoyancy, mucoadhesion, and in-vitro drug release were evaluated. To compare the bioavailability of improved formulations with the commercially available Dexilant®, in-vivo pharmacokinetic experiments were carried out in albino rabbits.

Results: Over a 12-hour period, the optimized floating microspheres (F17) demonstrated regulated drug release,…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free